FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:205-206 January 21, 1993 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The kidney is the principal source of erythropoietin, and renal failure represents a state of erythropoietin deficiency; patients with chronic renal failure have low plasma concentrations of erythropoietin relative to the severity of their anemia¹. Recombinant human erythropoietin is an effective treatment for anemia in these patients,^2,3 and it has few adverse effects. The chief exception is hypertension, which is readily controlled with antihypertensive medication. The paucity of adverse effects has two explanations. First, as a recombinant human molecule, erythropoietin does not elicit allergic responses. Second, erythroid progenitor cells appear to be the only target of the hormone. Because . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Eliopoulos, N., Gagnon, R. F., Francois, M., Galipeau, J. (2006). Erythropoietin Delivery by Genetically Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice with Chronic Renal Failure. J. Am. Soc. Nephrol. 17: 1576-1584 [Abstract] [Full Text]